Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials
Open accessPreprint — published as 10.1007/s40265-023-01841-4 · Paper page
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 17 of the 39 sources its claims cite were checked for support.
Abstract
Abstract Background Berberine is a nutraceutical that may improve lipid profiles. Berberine may also affect sex hormones and exert sex-specific effects, which has been overlooked. Objectives To comprehensively review the efficacy and safety of lipid-lowering effect of berberine with consideration of potential sex disparity. Methods Eligible studies were randomized controlled trials in adults that compared berberine versus placebo and measured blood lipids or lipoproteins. Studies were identified from Medline, Embase, Wanfang, CNKI, two clinical trial registries and previous systematic reviews. Mean differences (MD) were estimated using inverse variance weighting with random effects models. Risk of bias was assessed using the Cochrane risk of bias tool for randomized trials. Results 16 studies were included with treatment of 4 to 24 weeks. Berberine reduced low-density lipoprotein (LDL) cholesterol (−0.45 mmol/L, 95% CI -0.60 to -0.31, 12 studies, n=1,224), total cholesterol (−0.47 mmol/L, 95% CI -0.61 to -0.33, 15 studies, n=1,397), triglycerides (−0.32 mmol/L, 95% CI -0.44 to -0.19, 16 studies, n=1,421) and apolipoprotein B (−0.25 mg/dL, 95% CI -0.40 to -0.11, 2 studies, n=127). Berberine increased high-density lipoprotein (HDL) cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12, 13 studies, n=1,248). Notably, the effect on HDL cholesterol was different in women (0.11 mmol/L, 95% CI 0.09 to 0.13) from that in men (−0.07 mmol/L, 95% CI -0.16 to 0.02). Gastrointestinal adverse events were the most frequently reported adverse events. Conclusions Berberine decreased LDL cholesterol, triglycerides, and apolipoprotein B, with a potential sex-specific effect on HDL cholesterol. Large-scale trials considering sex disparity are required.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of 16 placebo-controlled randomized trials found that oral purified berberine improves lipid profiles in adults, lowering LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B while modestly raising HDL cholesterol. The effect on HDL cholesterol appeared sex-specific, favoring women over men, though the authors call for larger trials to confirm this.
Key findings
- Berberine reduced LDL cholesterol by −0.45 mmol/L (95% CI −0.60 to −0.31; 12 studies, n=1,224), total cholesterol by −0.47 mmol/L (95% CI −0.61 to −0.33; 15 studies, n=1,397), triglycerides by −0.32 mmol/L (95% CI −0.44 to −0.19; 16 studies, n=1,421), and apolipoprotein B by −0.25 mmol/L (95% CI −0.40 to −0.11; 2 studies, n=127).
- Berberine increased HDL cholesterol by 0.06 mmol/L (95% CI 0.00 to 0.12; 13 studies, n=1,248), with a sex-specific difference: women 0.11 mmol/L (95% CI 0.09 to 0.13) versus men −0.07 mmol/L (95% CI −0.16 to 0.02; P<0.01).
- Trim-and-fill adjustment for publication bias attenuated effects to −0.23 mmol/L (95% CI −0.42 to −0.05) for total cholesterol and −0.20 mmol/L (95% CI −0.37 to −0.03) for triglycerides.
- Gastrointestinal adverse events (constipation, diarrhea, nausea) appeared more frequent with berberine; no serious adverse events or muscle pain were reported in berberine groups. Withdrawal/discontinuation due to adverse events ranged from 2% to 6% of allocated patients in four studies.
Methods
- Study-level systematic review and meta-analysis (PROSPERO CRD42021293218) of randomized controlled trials comparing purified berberine with placebo in adults ≥18 years, excluding plant extracts, combination products, and non-placebo comparators.
- Searched MEDLINE, Embase, Wanfang, CNKI, ClinicalTrials.gov, and WHO ICTRP through December 2021, plus reference lists of prior reviews; 16 studies met eligibility (1,529 participants: 761 berberine, 768 placebo), with treatment durations of 4 to 24 weeks.
- Mean differences with 95% CIs pooled using inverse-variance random-effects models (R package meta); heterogeneity assessed with I², publication bias with funnel plots and Egger's test, and subgroup analyses by sex, trial duration, dose, and ethnicity; risk of bias via Cochrane RoB 2 and certainty via GRADE.
Limitations
- As stated by the authors: all eligible trials assessed surrogate lipid outcomes rather than cardiovascular events; follow-up was short (4–24 weeks), so long-term efficacy and safety remain unassessed; outcome reporting was potentially biased, with inconsistent reporting of lipid components and adverse events; and heterogeneity among pooled studies was high, addressed only through study-level subgroup analyses.
- Evident from the text: the sex-specific HDL finding rests on a small number of single-sex studies (one all-male study, four in women with PCOS), and the authors themselves note the possibility that greater statistical power in women rather than a true biological difference may explain the result; apoB analyses included only 2 studies (n=127).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
12 Valid · 0 Not valid · 9 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“testosterone lowers HDL cholesterol in men, which may partly explain why we did not find an increase in HDL cholesterol in men in this systematic review and meta-analysis.”
What the sources say
- Supportedcites [41] 41. Zhao J, Jiang C, Lam TH, Liu B, Cheng KK, Xu L, et al. Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J Epidemiol. 2014;43(1):140-8. source
The Results report that higher genetically predicted testosterone was associated with lower HDL cholesterol in men. The Introduction also reports that meta-analyses of trials in men found testosterone therapy decreased HDL cholesterol. (LLM, conf=0.90)
- Supportedcites [42] 42. Fernández -Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2010;95(6):2560-75. source
The Cardiovascular risk factors section reports significantly lower HDL cholesterol in testosterone-treated men than in controls. The Principal findings section describes the reduction as statistically significant but small. Page numbers are not provided in the supplied passages. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In our randomized controlled trial in Chinese men, berberine increased serum testosterone, whereas trials in women with polycystic ovary syndrome (PCOS) showed berberine decreased testosterone concentrations.(16-18)”
What the sources say
- Partly supportedcites [16] 16. Zhao JV, Yeung WF, Chan YH, Vackova D, Leung JYY, Ip DKM, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8). sourceExperimental — accuracy not yet measured
The Results report a statistically significant increase in testosterone when measurements at 8 and 12 weeks were analyzed together in the randomized trial of Chinese men. However, the Abstract and Conclusions describe the effect as a *possible* increase, so the unqualified claim is stronger than the paper's conclusion. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [17] 17. Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, et al. A clinical study on the shortterm effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99-105. source
- Not checked — no full text of the sourcecites [18] 18. An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425-31. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In our randomized controlled trial in Chinese men, berberine increased serum testosterone, whereas trials in women with polycystic ovary syndrome (PCOS) showed berberine decreased testosterone concentrations.(16-18)”
What the sources say
- Supportedcites [16] 16. Zhao JV, Yeung WF, Chan YH, Vackova D, Leung JYY, Ip DKM, et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. Nutrients. 2021;13(8). source
The Discussion reports that berberine supplementation lowered testosterone in women with PCOS in two trials. It also contrasts those findings with a possible increase in testosterone in the paper’s trial of men. No page number is provided in our copy. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [17] 17. Wei W, Zhao H, Wang A, Sui M, Liang K, Deng H, et al. A clinical study on the shortterm effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99-105. source
- Not checked — no full text of the sourcecites [18] 18. An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425-31. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was limited evidence of asymmetry for LDL and HDL cholesterol (Supplementary Figure 1B and 1D).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Consistent with previous systematic reviews, we did not identify any serious adverse events associated with berberine.(8, 10)”
What the sources say
- Not checked — no full text of the sourcecites [8] 8. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology. 2015;161:69-81. source
- Not checked — no full text of the sourcecites [10] 10. Ju J, Li J, Lin Q, Xu H. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
21 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 24
- It may state two separate claims as one. 33
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on efficacy · p. 11
“Funnel plots showed fewer trials on the right-hand side where berberine increased TC and TG (Supplementary Figure 1A and 1C)”
§ Supplementary Material · p. 23
“Supplementary Figure 1: Trim and fill funnel plots for total cholesterol (A), LDL cholesterol (B), HDL cholesterol (C) and triglycerides (D)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Abstract · p. 2
“apolipoprotein B (-0.25 mg/dL, 95% CI -0.40 to -0.11, 2 studies, n=127)”
§ Findings on efficacy · p. 10
“-0.25 mmol/L (95% CI -0.40 to -0.11, I 2 =82%; 2 studies, n=127 participants; low certainty; Figure 2E) for apoB”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on efficacy · p. 10
“-0.45 mmol/L (95% CI 0.60 to -0.31, I 2 =80%; 12 studies, n=1,224 participants; moderate certainty; Figure 2B) for LDL cholesterol”
§ Abstract · p. 2
“lowdensity lipoprotein (LDL) cholesterol (-0.45 mmol/L, 95% CI -0.60 to -0.31, 12 studies, n=1,224)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Findings on safety · p. 11
“see Supplementary File 5 for extracted adverse event data”
§ Supplementary Material · p. 23
“Supplementary File 4 - Adverse events raw data extraction”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Synthesis methods · p. 8
“trial duration ( ≤ 12 weeks, > 12 weeks)”
§ Subgroup Analyses · p. 12
“at different treatment durations ( ≥ 12 weeks, <12 weeks; Figure 4)”
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“Two reviewers assessed the risk of bias for each study using the Cochrane RoB 2 tool.(22) Risk of bias was judged as ‘low risk of bias’, ‘some concerns’, or ‘high risk’ of bias across five distinct study domains (bias arising from the randomization process, bias due to deviations from the intended interventions, bias…”
MethodThe PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874 · cited 1×
“(20) This report adheres to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement.(21) Covidence systematic review software (Veritas Health Innovation, Melbourne, Australia) was used to manage the entire review process and deduplicate studies.”
MethodWan, X., Wang, W., Liu, J., & Tong, T. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-135 · Cited by 11,735 · cited 2×
“We searched four databases, MEDLINE via Ovid, Embase via Ovid, Wanfang, and CNKI (China National Knowledge Infrastructure), and two clinical trial registries, ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform, from inception to December 2021, with an updated search to…”
MethodMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.03.001 · Cited by 4,265
Luo, D., Wan, X., Liu, J., & Tong, T. (2018) · Statistical Methods in Medical Research · doi:10.1177/0962280216669183 · Cited by 4,066 · cited 2×
“(23, 24) For studies that reported medians and interquartile ranges (IQR), we estimated the mean and SD as described in Luo and Wan.”
MethodESC/EAS Guidelines for the Management of Dyslipidaemias
Reiner, Ž., Catapano, A. L., Backer, G. D. D., et al. (2013) · doi:10.1016/j.repce.2012.12.001 · Cited by 2,682
Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391 · cited 2×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
BackgroundGlobal epidemiology of dyslipidaemias
Pirillo, A., Casula, M., Olmastroni, E., Norata, G. D., & Catapano, A. L. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00541-4 · Cited by 882
Adverse Effects of Testosterone Therapy in Adult Men: A Systematic Review and Meta-Analysis
Fernández-Balsells, M. M., Murad, M. H., Lane, M., Lampropulos, J. F., Albuquerque, F., Mullan, R. J., Agrwal, N., Elamin, M. B., Gallegos-Orozco, J. F., Wang, A. T., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2575 · Cited by 713
Treatment of Type 2 Diabetes and Dyslipidemia with the Natural Plant Alkaloid Berberine
Zhang, Y., Li, X., Zou, D., Liu, W., Yang, J., Zhu, N., Huo, L., Wang, M., Hong, J., Wu, P., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2404 · Cited by 573 · cited 3×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
BackgroundResultCurrent knowledge and pharmacological profile of berberine: An update
Kumar, A., Ekavali, Chopra, K., Mukherjee, M., Pottabathini, R., & Dhull, D. K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.068 · Cited by 530 · cited 1×
“Berberine is a pharmacologically active plant alkaloid that is present in several plants used in herbal medicine: goldenseal (Hydrastis canadensis), Coptis or goldenthread (Coptis chinensis), Oregon grape (Berberis aquifolium), barberry (Berberis vulgaris), and tree turmeric (Berberis aristata).(4) Nutraceutical suppl…”
BackgroundBiological properties and clinical applications of berberine
Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 496
Prevalence of statin intolerance: a meta-analysis
Bytyçi, I., Penson, P. E., Mikhailidis, D. P., Wong, N. D., Hernandez, A. V., Sahebkar, A., Thompson, P. D., Mazidi, M., Rysz, J., Pella, D., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac015 · Cited by 481 · cited 2×
“(2) However, nearly 10% of patients treated with statins experience statin intolerance and the odds of statin intolerance are greater in women and Asians.(3) Clinicians need to consider patient preferences in their decision making, and some patients may decide to use a non-prescription nutraceutical to manage their dy…”
BackgroundLan, J., Zhao, Y., Dong, F., Yan, Z., Zheng, W., Fan, J., & Sun, G. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2014.09.049 · Cited by 458
Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
Zhang, Y., Gu, Y., Ren, H., Wang, S., Zhong, H., Zhao, X., Ma, J., Gu, X., Xue, Y., Huang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18414-8 · Cited by 380 · cited 4×
“For studies that provided detailed results, we extracted the mean and standard deviation (SD) of the change in each group directly [28, 29].”
BackgroundMethodResultInfluentialPirillo, A., & Catapano, A. L. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.09.032 · Cited by 305
Repositioning of the global epicentre of non-optimal cholesterol
NCD Risk Factor Collaboration (NCD-RisC), Taddei, C., Zhou, B., Bixby, H., Carrillo-Larco, R. M., Danaei, G., Jackson, R. T., Farzadfar, F., Sophiea, M. K., Di Cesare, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2338-1 · Cited by 298 · cited 1×
“9 million deaths from ischemic heart disease and stroke in 2017.(1) Globally, statins are the most common treatment for dyslipidemia.”
BackgroundThe Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272
Méndez-del Villar, M., González-Ortiz, M., Martínez-Abundis, E., Pérez-Rubio, K. G., & Lizárraga-Valdez, R. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0082 · Cited by 246
Dong, H., Zhao, Y., Zhao, L., & Lu, F. (2013) · Planta Medica · doi:10.1055/s-0032-1328321 · Cited by 171 · cited 3×
“hypoglycemics, lifestyle modification), assessed extracts from the barberry plant or defined the intervention as combination nutraceutical products containing berberine such as Armolipid Plus®.(7-13) Moreover, the bioavailability of the different berberine preparations is a matter of .”
BackgroundMethodWei, W., Zhao, H., Wang, A., Sui, M., Liang, K., Deng, H., Ma, Y., Zhang, Y., Zhang, H., & Guan, Y. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0616 · Cited by 155 · cited 7×
“In a randomized controlled trial in Chinese men conducted by our team, berberine increased serum testosterone, whereas in trials in women with polycystic ovary syndrome (PCOS) berberine decreased testosterone concentrations [22–24].”
BackgroundInfluentialTrends in lipid-modifying agent use in 83 countries
Blais, J. E., Wei, Y., Yap, K. K. W., Alwafi, H., Ma, T.-T., Brauer, R., Lau, W. C. Y., Man, K. K. C., Siu, C. W., Tan, K. C. B., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.016 · Cited by 131
Self-citationJu, J., Li, J., Lin, Q., & Xu, H. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.09.212 · Cited by 124
Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion
Pérez-Rubio, K. G., González-Ortiz, M., Martínez-Abundis, E., Robles-Cervantes, J. A., & Espinel-Bermúdez, M. C. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0183 · Cited by 113 · cited 3×
“(18, 24, 33, 37) Although the overall number of any adverse events or proportion of patients with an adverse event were similar in five studies (23, 24, 29, 35, 37), gastrointestinal adverse events, such as constipation, diarrhea, and nausea, appeared”
BackgroundEffects of berberine on lipid profile in subjects with low cardiovascular risk
Derosa, G., D'Angelo, A., Bonaventura, A., Bianchi, L., Romano, D., & Maffioli, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.776037 · Cited by 112 · cited 4×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
BackgroundResultInfluentialCicero, A. F. G., Fogacci, F., Stoian, A. P., Vrablik, M., Al Rasadi, K., Banach, M., Toth, P. P., & Rizzo, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00955-y · Cited by 110 · cited 1×
“, statins), who do not want other lipid-modifying drug therapies, or in individuals at low cardiovascular risk who may benefit from moderate reductions in LDL or non-HDL cholesterol [8, 54].”
BackgroundYe, Y., Liu, X., Wu, N., Han, Y., Wang, J., Yu, Y., & Chen, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.653887 · Cited by 109
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
An, Y., Sun, Z., Zhang, Y., Liu, B., Guan, Y., & Lu, M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12294 · Cited by 105 · cited 7×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
BackgroundInfluentialTrends in lipid-modifying agent use in 83 countries
Blais, J., Wei, Y., Yap, K. K. K., et al. (2021) · medRxiv · doi:10.1101/2021.01.10.21249523 · Cited by 104 · cited 1×
“(1) Globally, statins are the most common treatment for dyslipidemia.(2) However, nearly 10% of patients treated with statins experience statin intolerance and the odds of statin intolerance are greater in women and Asians.”
BackgroundSelf-citationPirro, M., Vetrani, C., Bianchi, C., Mannarino, M. R., Bernini, F., & Rivellese, A. A. (2017) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.11.122 · Cited by 99
Adverse effects of testosterone therapy in adult men:A systematic review and meta-analysis
Zhang, M.-N. (2010) · doi:10.3760/cma.j.issn.1000-6699.2010.10.019 · Cited by 83
The Role of CXC Chemokines in Cardiovascular Diseases
Lu, X., Wang, Z., Ye, D., Feng, Y., Liu, M., Xu, Y. Q., Wang, M., Zhang, J., Liu, J., Zhao, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.765768 · Cited by 78
Fogacci, F., Grassi, D., Rizzo, M., & Cicero, A. F. G. (2019) · Phytotherapy Research · doi:10.1002/ptr.6282 · Cited by 61
Zhao, J. V., Yeung, W.-F., Chan, Y.-H., Vackova, D., Leung, J. Y. Y., Ip, D. K. M., Zhao, J., Ho, W.-K., Tse, H.-F., & Schooling, C. M. (2021) · Nutrients · doi:10.3390/nu13082550 · Cited by 58 · cited 3×
“As shown in a previous randomized controlled trial, berberine increases testosterone in men [22].”
BackgroundMethodSelf-citationZhao, J., Jiang, C., Lam, T. H., Liu, B., Cheng, K. K., Xu, L., Au Yeung, S. L., Zhang, W., Leung, G. M., & Schooling, C. M. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt239 · Cited by 53 · cited 1×
“Furthermore, a Mendelian randomization study [51] and a systematic review and meta-analysis of testosterone clinical trials [52] indicate that testosterone lowers HDL cholesterol in men, which may partly explain why we did not find an increase in HDL cholesterol in men in this systematic review and meta-analysis.”
BackgroundSelf-citationMing, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00942-7 · Cited by 52 · cited 5×
“Given its ability to reduce blood glucose, berberine was associated with more hypoglycemic events and fewer hyperglycemic events than placebo in four studies [29, 35, 43, 46].”
BackgroundMethodResultInfluentialSelf-citationZhang, L.-S., Zhang, J.-H., Feng, R., Jin, X.-Y., Yang, F.-W., Ji, Z.-C., Zhao, M.-Y., Zhang, M.-Y., Zhang, B.-L., & Li, X.-M. (2019) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x19500393 · Cited by 50 · cited 3×
“hypoglycemics, lifestyle modification), assessed extracts from the barberry plant or defined the intervention as combination nutraceutical products containing berberine such as Armolipid Plus®.(7-13) Moreover, the bioavailability of the different berberine preparations is a matter of .”
BackgroundMethodSniderman, A. D., Langlois, M., & Cobbaert, C. M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000754 · Cited by 50
Koppen, L. M., Whitaker, A., Rosene, A., & Beckett, R. D. (2017) · Journal of Evidence-Based Complementary & Alternative Medicine · doi:10.1177/2156587216687695 · Cited by 47
Schooling, C., Zhao, J., Au Yeung, S., & Leung, G. (2020) · eLife · doi:10.7554/elife.58567 · Cited by 39 · cited 1×
“Notably, it is increasingly realized that lipid-lowering drugs, such as statins, may exert sexspecific effects, possibly through sex hormones.(15) Berberine may also affect sex hormones, and therefore exert sex-specific effects.”
BackgroundSelf-citationLipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 35
Hadi, A., Arab, A., Ghaedi, E., Rafie, N., Miraghajani, M. S., & Kafeshani, M. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.01.017 · Cited by 34
Chan, M., Qin, Z., Man, S., Lam, M., Lai, W. H. E., Ng, R., Lee, C. K., Wong, T. L., Lee, E. H. M., Wong, H. K., et al. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13323 · Cited by 33
Variability in Potency Among Commercial Preparations of Berberine
Funk, R. S., Singh, R. K., Winefield, R. D., Kandel, S. E., Ruisinger, J. F., Moriarty, P. M., & Backes, J. M. (2018) · Journal of Dietary Supplements · doi:10.1080/19390211.2017.1347227 · Cited by 29 · cited 2×
“Fifth, although we included studies that used purified berberine rather than plant extract as the intervention, it is possible that the quality of berberine varies in different products, which may underestimate the effect of berberine [19, 20].”
BackgroundPu, Z., Sun, Y., Jiang, H., Hou, Q., Yan, H., Wen, H., & Li, G. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500920 · Cited by 29
Rashidi, H., Namjoyan, F., Mehraban, Z., Zakerkish, M., Ghaderian, S. B., & Latifi, S. M. (2018) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp.64180 · Cited by 28 · cited 3×
“2 shows records for each study).(16-18, 23, 24, 29, 31-40) All studies were conducted in young or middle-aged adults and none of the studies enrolled participants with a history of coronary artery disease or stroke.”
BackgroundLi, M., Liu, Y., Qiu, Y., Zhang, J., Zhang, Y., Zhao, Y., Jia, Q., & Li, J. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113899 · Cited by 21
Cicero, A. F. G., Kennedy, C., Knežević, T., Bove, M., Georges, C. M. G., Šatrauskienė, A., Toth, P. P., & Fogacci, F. (2021) · Nutrients · doi:10.3390/nu13020638 · Cited by 20
Casula, M., Catapano, A. L., & Magni, P. (2022) · Nutrients · doi:10.3390/nu14030606 · Cited by 17 · cited 1×
“This review can inform patients and clinicians of the totality of the currently best-available evidence for berberine, it can meet the needs of evidence-based clinical practice guideline recommendations for use of berberine for treatment of dyslipidemia,(19) and it can inform future research on berberine as an interve…”
BackgroundMarcheluzzo, S., Faggian, M., Zancato, M., & Peron, G. (2021) · Molecules · doi:10.3390/molecules26082222 · Cited by 13
Safety first, a harmful interaction between rivaroxaban and berberine
Bonnichsen, M. H., Stoklosa, T., Bowen, D. G., & Majumdar, A. (2022) · Internal Medicine Journal · doi:10.1111/imj.15774 · Cited by 4
Ming, J., Yu, X., Xu, X., Wang, L. S., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Figshare · doi:10.6084/m9.figshare.15132745
Self-citationФЕНОТИПИЧЕСКАЯ АДАПТАЦИЯ МОРСКИХ ЕЖЕЙ, ВЫРАЩЕННЫХ В УСЛОВИЯХ ОГРАНИЧЕННОГО ПРОСТРАНСТВА
Лиу, Р., Педлар, Ш., Од, А., et al. (2020) · Биофизика · doi:10.31857/s0006302920030163
Research works printed but not linked: 8
- 20. Blais J, Zhao JV, Huang X. Effect of berberine compared to placebo on lipid profiles: systematic review and meta-analysis of randomized controlled trials. PROSPERO; 2021. p. CRD42021293218.
- 34. Derosa G, D'Angelo A, Bonaventura A, Bianchi L, Romano D, Maffioli P. Effects of berberine on lipid profile in subjects with low cardiovascular risk. Expert Opin Biol Ther. 2013;13(4):475-82. It is made available under a CC-BY-NC-ND 4.0 International license . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) medRxiv preprint doi: https://doi.org/10.1101/2022.06.20.22276676; this version posted June 21, 2022. The copyright holder for this preprint
- 29. Li M, Li J, Liu Y, Zhao Y, Qiu Y, Jia Q, et al. The influence of berberine hydrochloride on glucolipid metabolism of patients with schizophrenia (Chinese). Chinese Journal of Prevention and Control of Chronic Diseases. 2016.
- 65. 33. Deng H, Wei W, Guan Y. The Clinical Study of Berberine in Patients with Polycystic Ovarian Syndrome and Insulin Resistance (Chinese). Tianjin Medical Journal. 2012;40(10):3.
- 36. Wang L, Peng LY, Wei GH, Ge H. Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia (Chinese). Chinese Journal of Integrated Traditional and Western Medicine. 2016;36(6):681-4.
- 37. Zhang J, Zhao Y, Jia Q, Liu Y, Li M, Li J, et al. Effect of berberine on symptoms and glycolipid metabolism in schizophrenia patients treated with risperidone (Chinese). Journal of Tianjin Medical University. 2016;22(4):338-40.
- 38. Zhu Q, Hu W, Dai C. Effects of berberine combined with ethinylestradiol cyproterone acetate in the treatment of obese women with polycystic ovary syndrome (Chinese). Chinese Journal of Primary Medicine and Pharmacy. 2016;23(6):837-40.
- 40. Hu J, Hu t, Wang j, Yu J, Wang J, Zhang Q. Effect of berberine combined with metformin on body fat distribution and liver fat content in type 2 diabetic patients with NAFLD (Chinese). Zhejiang Medicine. 2021;43(21):2327-31.
Cited by
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572197 · Cited by 24
Mechanisms of action and therapeutic potential of PCSK9-regulating drugs
Qi, C., Fan, D., Wang, L., Guo, L., Jiang, H., & Wang, L. (2025) · Pharmaceutical Biology · doi:10.1080/13880209.2025.2514021 · Cited by 7
Sharma, S., & Tanwar, S. S. (2026) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2026.100576 · Cited by 4
Metadata
- Authors
- Blais, J. E., Huang, X., & Zhao, J. V.
- Affiliations
- University of Hong Kong (HK)
- Corresponding author
- Zhao, Jie V
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2022-06-21
- Volume
- 83
- Issue
- 5
- Pages
- 403-427
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W4328048052
- Semantic Scholar
- b2ca75e2bf312edec24bb1836e8ceb0b9ac18d7e
- Cited by
- 31
- References
- 33
- Citations by year
- 2026: 12 · 2025: 13 · 2024: 4 · 2023: 2
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Drugs (publishedVersion)
- medRxiv (submittedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Natural Products and Biological Research
- Keywords
- berberine, dyslipidemia, hypolipidemic effect, sex differences, HDL cholesterol, LDL cholesterol, triglycerides, apolipoprotein B, total cholesterol, nutraceuticals, gastrointestinal adverse effects, drug safety, cardiovascular risk reduction, risk of bias assessment, quality of evidence grading, heterogeneity
- MeSH terms
- Adult, Apolipoproteins, Berberine, Cholesterol, Female, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Triglycerides, Randomized Controlled Trials as Topic, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.






